Big Pharma has aimed some choice words at European countries in recent weeks, including calling the UK “uninvestable” and ...

AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...

Delaware courts issued multiple instructive decisions on earnout provisions in life sciences M&A transactions.

Spain ranks first in Europe for clinical trials and is attracting investment in life sciences, but faces intense competition ...

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is still trading at three-year highs, despite current market volatility, in ...

EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...

Alexion, AstraZeneca Rare Disease treatment Ultomiris® (ravulizumab rch) has become the first targeted treatment option to be reimbursed for people ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver ...

WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with ...

BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval: Palo Alto, California Monday, March 31, 2025, 17:00 Hrs [IST] Bri ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...